Phase II trial of bleomycin in patients with advanced ovarian cancer: an EORTC gynecological cancer cooperative group study

J. B. Vermorken, J. P. Armand, A. J. Lacave, M. George, C. F. de Oliveira, F. Cheix, A. P. Maskens, N. Rotmensz

Research output: Contribution to journalArticlepeer-review

Abstract

Bleomycin was administered by continuous i.v. infusion at a dose of 20 mg/m2/day for 7 days to 18 evaluable patients with advanced ovarian epithelial cancer resistant to conventional chemotherapy. The toxicity pattern was no different from that known from earlier studies using continuous infusion of bleomycin with the exception of the occurrence of a life-threatening allergic reaction in one patient, which led to discontinuation of treatment after 3 days. Only one patient showed a partial response of 2 months (5.5%), indicating that the drug has no significant activity in this unfavorable group of patients.

Original languageEnglish
Pages (from-to)671-673
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of bleomycin in patients with advanced ovarian cancer: an EORTC gynecological cancer cooperative group study'. Together they form a unique fingerprint.

Cite this